FDA · EMA · TİTCK Inspection Readiness

Three regulators, one standard: Audit-Ready Clinical Trials

FDA is tightening foreign inspections, the EU is bringing third-country trials into inspection scope, and TİTCK is running risk-based GCP inspections. Omega CRO has met the expectations of all three under one operational roof since 1997: Part 11-compliant data, inspection readiness and regulatory dossier expertise.

Book a 30-Minute Discovery Call Explore the Inspection Readiness Package
Three Regulators, One Readiness

The inspection bar is rising on three fronts

The same trial's data is inspected separately in US, EU and Turkish dossiers. One readiness programme covers all three regulators.

FDA — United States

FDA

September 2026 editorial by four FDA center directors: "Good Clinical Practices Are Not Optional."

  • Foreign BIMO inspections are expanding.
  • Marketing authorization requires access to sites, source data and consent documentation.
  • Informed consent scrutiny is rising.
  • Congressional pressure continues to restrict certain foreign clinical data.
  • FDA's message: do not build regulatory strategy around data you cannot inspect.

EMA — EU

EMA

Under Regulation (EU) 536/2014 and Implementing Regulation (EU) 2017/556, GCP inspections are carried out by Member States on behalf of the EU and recognised by all Member States; EMA coordinates for the centralised procedure.

  • Third-country inspections: Trials conducted in third countries can be inspected when referenced in EU authorisation applications — verifying equivalence to EU standards.
  • Triggers are defined: third-country location, complex protocols, first-time-inspected sites and negative FDA inspection outcomes can trigger "for cause" inspections.
  • Joint inspections expanding: FDA-EMA-MHRA-PMDA cooperation is growing — findings in one authority increasingly carry weight in another.
  • Serious breaches: reportable via CTIS within 7 days; inspection records retained 25 years.
  • Agenda: the Biotech Act draft targets approval timelines of 106→75 days; CTIS is being renewed in 2027; ICH E6(R3) Annex 2 applies from 15 January 2027.

TİTCK — Türkiye

TİTCK

TİTCK runs risk-based GCP inspections, processes applications through its Clinical Trials Module and centralises ethics committee pathways.

  • Risk-Based GCP Inspection Guide: inspection resources follow the risk profile — predictable, not a surprise, for prepared sites.
  • Trust Practices Guide for Applications: GCP inspection reports issued by Competent Authorities (FDA, EMA etc.) are accepted by TİTCK — absent violations of Turkish legislation, TİTCK does not conduct its own GCP inspection. A strong foreign inspection report prevents double inspection.
  • Application infrastructure: KAD-KLVZ-02 (trial applications), KAD-KLVZ-03 (ethics committees), Clinical Trials Module/Portal, EBS electronic application system.
  • Phase 1 centres: TİTCK issues activity permits for Phase 1 clinical research centres.
  • 2026 agenda: Clinical Trials Advisory Board standard operating methods (January 2026), the "İlaçta Güvenli Dönüşüm" programme, and the e-Ledger obligation for MAHs (15 December 2026).

The common threshold: all three regulators want the same things — source data access, complete audit trails, documented consent, traceable IP chains and demonstrated sponsor oversight. Omega closes that threshold in one package.

Why Türkiye

Türkiye is an inspectable region for all three regulators

1.Inspectable

FDA and EU member states can inspect sites and access records; full alignment with 21 CFR 312.120 and EU CTR frameworks.

2.Ally & framework

NATO ally, ICH member, GCP-aligned TİTCK framework, EU candidate.

3.Speed & access

Large patient pool, strong investigator network, fast enrollment in multi-center trials.

4.One accountable partner

Omega CRO: direct TİTCK and ethics committee submission experience, US office, EU CTR 536/2014 compliance, Part 11 EDC, central lab, pharmacovigilance and home-care ecosystem.

Why Omega CRO

Proven infrastructure, capabilities aligned to three regulators

Since 1997

Türkiye's first CRO; offices in the US, Canada, Azerbaijan, Poland and Kosovo.

Scale

200+ full-time specialists; 50+ mid-to-large studies per year; 400+ investigator-initiated studies.

Regulatory expertise

TİTCK submissions, ethics committee (KAEK) applications, EU CTR 536/2014 compliance, FDA 21 CFR Part 11, IND/CTA, SUSAR XML reporting, global regulatory strategy.

Data integrity

FDA 21 CFR Part 11-compliant EDC/eCRF with full audit trails; ALCOA+ data management.

Inspection readiness

Risk-based monitoring aligned with ICH E6(R3); deviation & CAPA management; audit readiness practice.

Clinical supply

Omega Depot (Ankara): licensed IMP depot since 2003; cold chain; IWRS/IXRS.

Science

HelixLab central laboratory; Omega Genetics genomics; multi-region biorepository.

Pharmacovigilance

Full pharmacovigilance: PV setup, ICSR, SUSAR, PSUR/PBRER, RMP.

Innovation

TURP remote patient monitoring; Omega Care licensed home nursing; PRO/ePRO.

The Package

Multi-Regulator Inspection Readiness — three-tier package

Each tier can be purchased standalone; together they close inspection risk across FDA, EMA and TİTCK dossiers end to end.

Tier 1

Site Readiness

4–6 weeks per site

  • Gap assessment vs 21 CFR 312, ICH E6(R3) and EU CTR 536/2014
  • Mock FDA/BIMO or EU GCP inspection with closeout simulation
  • Source data & ALCOA+ remediation plan
  • IEC/informed consent file QC against both FDA and EU Chapter V standards
  • IP accountability & depot process verification
  • Investigator & staff GCP training with written commitments
  • CAPA plan & inspection response discipline training
Request a Quote
Tier 2

Program Readiness

8–12 weeks per program

  • Data integrity & Part 11 EDC audit trail verification
  • 312.120(b)(10)-(11) sponsor monitoring documentation and investigator commitments
  • IEC designation and membership documentation
  • Inspectionability Dossier for FDA pre-submission and EMA CHMP assessment
  • Foreign data provenance map
  • CTIS serious breach reporting procedure (7-day discipline)
  • TİTCK Trust Practices package — competent-authority GCP inspection reports packaged for TİTCK submission (preventing double inspection)
  • Risk-based monitoring plan revision aligned with E6(R3) and TİTCK risk-based guide
Request a Quote
Tier 3

Standing Inspection Support

Monthly retainer / project-based

  • Inspection war-room with 24-hour activation
  • Form FDA 483 response (15-business-day discipline); EU inspection report responses
  • CAPA verification & closure audit
  • Inspection classification monitoring & crisis communications
  • Monthly FDA, EMA and TİTCK intelligence brief (joint inspections, trigger changes, legislative updates)
  • TİTCK legislative tracking: e-Ledger transition (15 Dec 2026), Advisory Board methods, Clinical Trials Module updates
  • Foreign inspection pre-announcement protocol
Request a Quote

Pricing is determined by the sponsor's scale and scope.

Regulator Comparison

FDA vs EMA vs TİTCK — the inspection framework at a glance

Aspect FDA (US) EMA (EU) TİTCK (Türkiye)
Who inspects FDA BIMO program (US + foreign offices) Member States on behalf of the EU; EMA coordinates centralised procedures TİTCK (risk-based GCP inspections)
Triggers Rising foreign inspections; marketing authorisation review; for-cause Third-country location, complex protocols, first-time-inspected sites, negative FDA information Risk profile; application trust assessment; absent Competent Authority report
Critical documents Source data, audit trail, consent, IP accountability, sponsor oversight Chapter V consent, IEC, risk mitigation plan, CSR, serious breach records KAD-KLVZ-02/03 dossiers, ethics committee consent, Competent Authority GCP report
Unique advantage 312.120(b) commitment documents Competent authority inspection reports recognised across the EU Trust Practices: if an FDA/EMA GCP report is submitted, TİTCK does not run its own inspection
Records / reporting 312.62 records; 483 response within 15 business days Inspection records 25 years; serious breach via CTIS in 7 days Legislation and application records; e-Ledger (Dec 2026)
Evidence Map

Most-cited findings — the Omega response

Finding Theme Typical Findings Omega Response
Protocol compliance Wrong/missed procedures, out-of-window visits Risk-based monitoring, digital visit tracking
Source data Inconsistent, non-contemporaneous records Part 11 EDC, full audit trail, ALCOA+
AE reporting Delayed/missing notifications PV team, ICSR automation, CTIS reporting
IP accountability Missing return/destruction records Omega Depot licensed chain + IWRS
IEC/IRB/KAEK Consent expiry, missing notifications Ethics committee submission management, consent tracking
Data integrity Insufficient audit trail, ineffective CAPA EDC audit trail design + CAPA management
Sponsor oversight Insufficient monitoring, untrained staff Project & quality management, training programmes
Informed consent Failure to document freely-given consent Standard consent file + site verification
Process

How we work

1

Discovery

Program goals (which FDA/EU/Turkish dossiers are targeted), data provenance and inspection risk mapping (30-min call).

2

Gap Analysis

Site and program-level assessment with a prioritized findings list and authority-specific risk matrix.

3

Readiness

Remediation, training, mock inspection and documentation package aligned to all three regulators.

4

Support

War-room during inspections, response discipline, CAPA verification and continuous intelligence (FDA + EMA + TİTCK).

FAQ

Frequently Asked Questions

How do FDA inspections work in Türkiye?
FDA inspects foreign investigator sites under its BIMO program, generally with pre-announcement; findings are documented on Form FDA 483. Omega manages readiness and on-site coordination throughout.
How are EMA inspections triggered?
EU GCP inspections are carried out by Member States and recognised across the EU. Third-country trials referenced in EU applications can be inspected; third-country location, complex protocols and negative FDA outcomes can trigger "for cause" inspections. Omega analyses your triggers and structures readiness accordingly.
Does TİTCK accept FDA or EMA inspection reports?
Yes. Under TİTCK's Trust Practices Guide, GCP inspection reports from Competent Authorities are accepted; absent violations, TİTCK does not run its own GCP inspection. Omega packages these reports for TİTCK submission.
What is a serious breach?
Non-compliance seriously affecting subject safety, rights or data integrity; reportable via CTIS within 7 days. Omega sets up the assessment and reporting procedure with your PV team.
What does 21 CFR 312.120 vs EU CTR require?
Both demand inspectable foreign data, but the document sets differ: FDA's 312.120(b) commitments versus the EU's Chapter V consent, IEC, risk mitigation plan and serious breach records. Omega produces both in one program.
Why is Part 11 EDC important?
Electronic records need reliable audit trails and access controls; insufficient audit trails are among the most cited findings across all three regulators.
What does a mock inspection involve?
A 4–6 week preparation period followed by a 2–3 day on-site mock inspection in the target authority's format (FDA/EU/TİTCK), with a closeout simulation and CAPA plan.
How do we assess our inspection risk?
Book a free 30-minute discovery call; we run a rapid pre-assessment and produce an authority-specific risk map.

Close your inspection risk. Strengthen your submission.

Work with a team ready for FDA, EMA and TİTCK expectations. In a 30-minute discovery call we'll map your program's inspection risk.

Book a 30-Minute Discovery Call Контакты

or [email protected]

Related Services

Quality Assurance & Compliance → Project & Quality Management →